Clinical trials: Dapagliflozin
End-stage Kidney Disease
DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease
Treatment with sodium glucose co-transporter type 2 inhibitors (Sglt2i) reduced the incidence of cardiovascular death and hospitalization for heart failure by 29% in individuals with moderate chronic kidney disease.
- Trial name
- Dare-Esrd (NCT05685394)
- Testing
- Dapagliflozin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes Mellitus
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
- Trial name
- NCT00855166
- Testing
- Dapagliflozin, Metformin, Sitagliptin
- Where
- 21 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis
A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.
The purpose of this study is to investigate the mechanistic effects of dapagliflozin 10 mg, alone or in combination with balcinrenone 150 mg, with balcinrenone 150 mg and placebo, on the way the body handles electrolytes and…
- Conditions
- Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Chronic Kidney Disease Stage 3, Electrolyte and Fluid Balance Conditions
- Trial name
- DapaBalci-Leap (NCT05884866)
- Testing
- Dapagliflozin 10mg Tab, Balcinrenone 50mg Capsule, Balcinrenone 100mg Capsule
- Where
- 2 sites in France, Germany
- Volunteers
- 103 people
- Sponsor
- Klinikum Nürnberg
Type 2 Diabetes Mellitus
SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
This study evaluates the metabolomics changes associated with dapagliflozin treatment in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03919656
- Testing
- Dapagliflozin 10 mg
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Type 2 Diabetes Mellitus
Effect of Dapagliflozin on Inflammation and Endothelial Function
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduce hyperglycemia and improve peripheral insulin sensitivity by ameliorating glucotoxicity.
- Trial name
- NCT02608905
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Type 2 Diabetes Mellitus
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus
- Trial name
- DERISC (NCT02426541)
- Testing
- Dapagliflozin
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Cardiovascular Kidney Metabolic Syndrome
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Complex pathophysiological interactions among obesity, metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system lead to poor cardiovascular-kidney-metabolic health (CKMH), which is a major determinant…
- Trial name
- DASH-CKMH (NCT07188545)
- Testing
- Intervention, Active Comparator
- Where
- United States
- Volunteers
- 23,280,000 people
- Sponsor
- Ohio State University
Heart Failure, Diabetic Cardiomyopathies
The DAPA-MEMRI Trial
Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle…
- Trial name
- DAPA-MEMRI (NCT04591639)
- Testing
- Dapagliflozin 10 milligrams [Farxiga]
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Renal Insufficiency, Chronic, Cardiac Catheterization
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as…
- Conditions
- Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
- Trial name
- NCT05225077
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Diabetic Macular Edema, Center-involved Diabetic Macular Edema
Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema
The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement…
- Trial name
- DAPA-DME (NCT06845163)
- Testing
- Dapagliflozin, Anti-VEGF drug
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Alexandria University
Congestive Heart Failure
Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of renal function in acute decompensation of chronic heart failure (ADHF) compared to standard therapy will be analyzed.
- Trial name
- NCT04778787
- Testing
- Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
- Where
- 2 sites in Russia
- Volunteers
- 370 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes.
- Trial name
- SFRNDM2 (NCT05139914)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Liver Cirrhosis
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as…
- Trial name
- ZEAL UNLOCK (NCT06269484)
- Testing
- Zibotentan + dapagliflozin
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
Left Cardiac Catheterization, Percutaneous Coronary Intervention
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
Left heart catheterization and percutaneous coronary intervention (PCI) has become a useful tool in interventional cardiology, in which iodinated contrast media is used.
- Conditions
- Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury, Sodium-glucose Co-transporter 2 Inhibitors
- Trial name
- NCT04806633
- Testing
- Dapagliflozin 5mg
- Where
- 2 sites in Greece
- Volunteers
- 1,722 people
- Sponsor
- G.Gennimatas General Hospital
Hepatocellular Carcinoma (HCC)
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
The goal of this interventional study (clinical trial) is to evaluate the efficacy and safety of adding dapagliflozin to first-line standard therapy in patients with unresectable hepatocellular carcinoma (HCC) and comorbid…
- Trial name
- NCT07729592
- Testing
- Dapagliflozin, Donafenib, Tislelizumab
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes
Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients
This study is a non-interventional, multicentre, prospective, observational study to be conducted at 50 sites in India. The study targets to enrol 2000 patients with 40 patients per site.
- Trial name
- FOREFRONT (NCT03071016)
- Where
- 29 sites in India
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Evaluate Ketogenic Stress
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
The study investigations include evaluation of the acute effects of a single dose of dapagliflozin (10mg), exenatide (5µg), a combination of exenatide and dapagliflozin or placebo under insulinopenic condition and the long term…
- Trial name
- NCT02962492
- Testing
- Exenatide/Exenatide extended release, Dapagliflozin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University at Buffalo
Type 2 Diabetes
Add-on to Thiazolidinedione (TZD) Failures
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone.
- Trial name
- NCT00683878
- Testing
- Dapagliflozin, Thiazolidinedione (Pioglitazone)
- Where
- 89 sites in United States, Argentina and 7 more
- Volunteers
- 972 people
- Sponsor
- AstraZeneca
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using…
- Trial name
- ACHIEVE-2 (NCT06192108)
- Testing
- Orforglipron, Dapagliflozin
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 962 people
- Sponsor
- Eli Lilly and Company